Krausz RM, Westenberg JN, Ziafat K. The opioid overdose crisis as a global health challenge. Curr Opin Psychiatry. 2021;34(4):405–12.
Article
Google Scholar
Ciccarone D. Fentanyl in the US heroin supply: a rapidly changing risk environment. Int J Drug Policy. 2017;46:107–11.
Article
Google Scholar
Krausz M, Westenberg JN, Mathew N, Budd G, Wong JSH, Tsang VWL, et al. Shifting North American drug markets and challenges for the system of care. Int J Ment Health Syst. 2021;15(1):86.
Article
Google Scholar
Suzuki J, El-Haddad S. A review: fentanyl and non-pharmaceutical fentanyls. Drug Alcohol Depend. 2017;171:107–16.
Article
CAS
Google Scholar
Carroll JJ, Marshall BDL, Rich JD, Green TC. Exposure to fentanyl-contaminated heroin and overdose risk among illicit opioid users in Rhode Island: A mixed methods study. Int J Drug Policy. 2017;46:136–45.
Article
Google Scholar
Morales KB, Park JN, Glick JL, Rouhani S, Green TC, Sherman SG. Preference for drugs containing fentanyl from a cross-sectional survey of people who use illicit opioids in three United States cities. Drug Alcohol Depend. 2019;204(107547):1–8.
Google Scholar
Martinez S, Jones JD, Brandt L, Campbell ANC, Abbott R, Comer SD. The increasing prevalence of fentanyl: a urinalysis-based study among individuals with opioid use disorder in New York City. Am J Addict. 2021;30(1):65–71.
Article
Google Scholar
Ferguson M, Parmar A, Papamihali K, Weng A, Lock K, Buxton JA. Investigating opioid preference to inform safe supply services: a cross sectional study. Int J Drug Policy. 2022;101:103574.
Article
Google Scholar
Bohnert ASB, Lin LA. It is time to recognize that synthetic opioids are not going away. Addiction. 2021;116:1313–8.
Article
Google Scholar
Morris NP. Opioid use disorder treatment in the age of fentanyl. JAMA Intern Med. 2022. https://doi.org/10.1001/jamainternmed.2021.8114.
Article
PubMed
Google Scholar
Thakrar AP. Short-acting opioids for hospitalized patients with opioid use disorder. JAMA Intern Med. 2022. https://doi.org/10.1001/jamainternmed.2021.8111.
Article
PubMed
Google Scholar
Weimer M, Morford K, Donroe J. Treatment of opioid use disorder in the acute hospital setting: a critical review of the literature (2014–2019). Curr Addict Rep. 2019;6(4):339–54.
Article
Google Scholar
Nolan NS, Marks LR, Liang SY, Durkin MJ. Medications for opioid use disorder associated with less against medical advice discharge among persons who inject drugs hospitalized with an invasive infection. J Addict Med. 2021;15(2):155–8.
Article
Google Scholar
Silverstein SM, Daniulaityte R, Martins SS, Miller SC, Carlson RG. “Everything is not right anymore”: buprenorphine experiences in an era of illicit fentanyl. Int J Drug Policy. 2019;74:76–83.
Article
Google Scholar
Moreno JL, Wakeman SE, Duprey MS, Roberts RJ, Jacobson JS, Devlin JW. Predictors for 30-day and 90-day hospital readmission among patients with opioid use disorder. J Addict Med. 2019;13(4):306–13.
Article
Google Scholar
Carusone SC, Guta A, Robinson S, Tan DH, Cooper C, O’Leary B, et al. “Maybe if I stop the drugs, then maybe they’d care?”—hospital care experiences of people who use drugs. Harm Reduct J. 2019;16(1):1–10.
Article
Google Scholar
Merchant E, Burke D, Shaw L, Tookes H, Patil D, Barocas JA, et al. Hospitalization outcomes of people who use drugs: one size does not fit all. J Subst Abuse Treat. 2020;112:23–8.
Article
Google Scholar
Mackay L, Kerr T, Fairbairn N, Grant C, Milloy M-J, Hayashi K. The relationship between opioid agonist therapy satisfaction and fentanyl exposure in a Canadian setting. Addict Sci Clin Pract. 2021;16(1):26.
Article
Google Scholar
Bardwell G, Wood E, Brar R. Fentanyl assisted treatment: a possible role in the opioid overdose epidemic? Subst Abuse Treat Prev Policy. 2019;14(1):50. https://doi.org/10.1186/s13011-019-0241-2.
Article
PubMed
PubMed Central
Google Scholar
Krausz RM, Westenberg JN, Vogel M. Addressing fentanyl use disorder with fentanyl-assisted treatment? Lancet Psychiatry. 2021;9(2):103–5.
Article
Google Scholar
Humphreys K, Shover CL, Andrews CM, Bohnert ASB, Brandeau ML, Caulkins JP, et al. Responding to the opioid crisis in North America and beyond: recommendations of the Stanford-Lancet Commission. Lancet. 2022;399(10324):555–604. https://doi.org/10.1016/S0140-6736(21)02252-2.
Article
PubMed
Google Scholar
British Columbia Centre on Substance Use (BCCSU) and British Columbia Ministry of Health. Guidance for injectable opioid agonist treatment for opioid use disorder. Vancouver, BC; 2021. https://www.bccsu.ca/wp-content/uploads/2021/07/BC_iOAT_Guideline.pdf
Fairbairn N, Ross J, Trew M, Meador K, Turnbull J, MacDonald S, et al. Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline. Can Med Assoc J. 2019;191(38):E1049–56.
Article
Google Scholar
Oviedo-Joekes E, MacDonald S, Boissonneault C, Harper K. Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study. Subst Abuse Treat Prev Policy. 2021;16(1):1–7.
Article
Google Scholar
McAdam M, Brar R, Young S. Initiation of injectable opioid agonist treatment in hospital: a case report. Drug Alcohol Rev. 2020;39(2):138–41.
Article
Google Scholar
Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A, et al. Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med. 2009;361(8):777–86.
Article
CAS
Google Scholar
Oviedo-Joekes E, Guh D, Brissette S, Marchand K, MacDonald S, Lock K, et al. Hydromorphone compared with diacetylmorphine for long-term opioid dependence. JAMA Psychiat. 2016;73(5):447–55.
Article
Google Scholar
Strang J, Groshkova T, Uchtenhagen A, van den Brink W, Haasen C, Schechter MT, et al. Heroin on trial: systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction. Br J Psychiatry. 2015;207(1):5–14.
Article
Google Scholar
Haasen C, Verthein U, Degkwitz P, Berger J, Krausz M, Naber D. Heroin-assisted treatment for opioid dependence. Br J Psychiatry. 2007;191(1):55–62.
Article
Google Scholar
Oviedo-Joekes E, Guh D, Brissette S, Marsh DC, Nosyk B, Krausz M, et al. Double-blind injectable hydromorphone versus diacetylmorphine for the treatment of opioid dependence: a pilot study. J Subst Abuse Treat. 2010;38(4):408–11.
Article
Google Scholar
Azar P, Mathew N, Mahal D, Wong JSH, Westenberg JN, Schutz C. Developing a rapid transfer from opioid full agonist to buprenorphine: ‘Ultrarapid Micro-Dosing’’ proof of concept’. J Psychoactive Drugs. 2022. https://doi.org/10.1080/02791072.2022.2039814.
Article
PubMed
Google Scholar
Ely EW, Truman B, Shintani A, Thomason JWW, Wheeler AP, Gordon S, et al. Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond Agitation-Sedation Scale (RASS). JAMA. 2003;289(22):2983–91.
Article
Google Scholar
Neimark G, Tjoa C. Treating fentanyl withdrawal. J Behav Health Serv Res. 2020;47(4):614–5.
Article
Google Scholar
Azar P, Nikoo M, Miles I. Methadone to buprenorphine/naloxone induction without withdrawal utilizing transdermal fentanyl bridge in an inpatient setting—Azar method. Am J Addict. 2018;27(8):601–4.
Article
Google Scholar
Klaire S, Zivanovic R, Barbic SP, Sandhu R, Mathew N, Azar P. Rapid micro-induction of buprenorphine/naloxone for opioid use disorder in an inpatient setting: a case series. Am J Addict. 2019;28(4):262–5.
Article
Google Scholar
Wong JSH, Nikoo M, Westenberg JN, Suen JG, Wong JYC, Krausz RM, et al. Comparing rapid micro-induction and standard induction of buprenorphine/naloxone for treatment of opioid use disorder: protocol for an open-label, parallel-group, superiority, randomized controlled trial. Addict Sci Clin Pract. 2021;16(1):11. https://doi.org/10.1186/s13722-021-00220-2.
Article
PubMed
PubMed Central
Google Scholar
Marchand K, Foreman J, MacDonald S, Harrison S, Schechter MT, Oviedo-Joekes E. Building healthcare provider relationships for patient-centered care: a qualitative study of the experiences of people receiving injectable opioid agonist treatment. Subst Abuse Treat Prev Policy. 2020;15(1):7. https://doi.org/10.1186/s13011-020-0253-y.
Article
PubMed
PubMed Central
Google Scholar
Boles SM, Miotto K. Substance abuse and violence: a review of the literature. Aggress Violent Behav. 2003;8(2):155–74.
Article
Google Scholar
Antoine D, Huhn AS, Strain EC, Turner G, Jardot J, Hammond AS, et al. Method for successfully inducting individuals who use illicit fentanyl onto buprenorphine/naloxone. Am J Addict. 2021;30(1):83–7.
Article
Google Scholar
Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw open. 2020;3(2):e1920622.
Article
Google Scholar
Ferri M, Davoli M, Perucci CA. Heroin maintenance for chronic heroin-dependent individuals. Cochrane Database Syst Rev. 2010;8:CD003410.
Google Scholar
Boyd S, Murray D, MacPherson D. Telling our stories: heroin-assisted treatment and SNAP activism in the Downtown Eastside of Vancouver. Harm Reduct J. 2017;14(1):1–14.
Article
Google Scholar